| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - TIMP-1 (tissue inhibitor of metalloproteinases 1) regulates not only extracellular matrix catabolism but the major effect in tumor tissue is promotion of cell growth and anti-apoptotic activity. The aim of our study was to evaluate TIMP-1 plasma levels and tissue TIMP-1 mRNA expression as a prognostic marker in NSCLC patients. Methods: We studied a group of 108 patients with NSCLC who had undergone lung surgery. Quantitative estimation analysis of TIMP-1 mRNA was performed using RT real-time PCR. Quantitative estimation of plasma TIMP-1 protein was performed using ELISA. Results: There was shorter disease free interval (DFI) in NSCLC patients at stage II with a higher expression of TIMP-1 mRNA in tumor tissue (p{0.0001). We found there to be a statisticaly significant relation between TIMP-1 mRNA tumor tissue expression and DFI in SCC (p{0.0001). We also found shorter overall survival (OS) in patients at stages IIIa + IIIb + IV with a higher expression of TIMP-1 mRNA (p=0.0389). We found statistically significant differences in TIMP-1 plasma levels between SCC and adenocarcinoma NSCLC patients (p=0.0491). We did not record any relationship between TIMP-1 plasma levels and prognosis (DFI, OS) in any studied group. Conclusion: We found there to be a relationship between TIMP-1 mRNA expression in NSCLC tumor tissue and prognosis. Higher tissue level of TIMP-1 is related to an adverse prognosis of patients. However, our results did not show the relation of TIMP-1 protein in blood plasma of patients with NSCLC to prognosis.
- TIMP-1 (tissue inhibitor of metalloproteinases 1) regulates not only extracellular matrix catabolism but the major effect in tumor tissue is promotion of cell growth and anti-apoptotic activity. The aim of our study was to evaluate TIMP-1 plasma levels and tissue TIMP-1 mRNA expression as a prognostic marker in NSCLC patients. Methods: We studied a group of 108 patients with NSCLC who had undergone lung surgery. Quantitative estimation analysis of TIMP-1 mRNA was performed using RT real-time PCR. Quantitative estimation of plasma TIMP-1 protein was performed using ELISA. Results: There was shorter disease free interval (DFI) in NSCLC patients at stage II with a higher expression of TIMP-1 mRNA in tumor tissue (p{0.0001). We found there to be a statisticaly significant relation between TIMP-1 mRNA tumor tissue expression and DFI in SCC (p{0.0001). We also found shorter overall survival (OS) in patients at stages IIIa + IIIb + IV with a higher expression of TIMP-1 mRNA (p=0.0389). We found statistically significant differences in TIMP-1 plasma levels between SCC and adenocarcinoma NSCLC patients (p=0.0491). We did not record any relationship between TIMP-1 plasma levels and prognosis (DFI, OS) in any studied group. Conclusion: We found there to be a relationship between TIMP-1 mRNA expression in NSCLC tumor tissue and prognosis. Higher tissue level of TIMP-1 is related to an adverse prognosis of patients. However, our results did not show the relation of TIMP-1 protein in blood plasma of patients with NSCLC to prognosis. (en)
|
| Title
| - Prognostic Significance of TIMP-1 in Non-small Cell Lung Cancer
- Prognostic Significance of TIMP-1 in Non-small Cell Lung Cancer (en)
|
| skos:prefLabel
| - Prognostic Significance of TIMP-1 in Non-small Cell Lung Cancer
- Prognostic Significance of TIMP-1 in Non-small Cell Lung Cancer (en)
|
| skos:notation
| - RIV/00216208:11140/11:10106113!RIV12-MZ0-11140___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(NS10230), S, Z(MSM0021620819)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| - Vrzalová, Jindra
- Topolčan, Ondřej
- Pešek, Miloš
- Holubec, Luboš
- Šafránek, Jarmil
- Liška, Václav
- Třeška, Vladislav
- Pecen, Ladislav
- Pešta, Martin
- Vyčítal, Ondřej
- Brůha, Jan
- Kučera, Radek
- Kulda, Vlastimil
- Pražáková, Markéta
|
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11140/11:10106113
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Cancer; Lung; Cell; Non-small; TIMP-1; Significance; Prognostic (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Liška, Václav
- Pešek, Miloš
- Třeška, Vladislav
- Topolčan, Ondřej
- Vrzalová, Jindra
- Šafránek, Jarmil
- Brůha, Jan
- Holubec, Luboš
- Pecen, Ladislav
- Pešta, Martin
- Vyčítal, Ondřej
- Kučera, Radek
- Kulda, Vlastimil
- Pražáková, Markéta
|
| http://linked.open...ain/vavai/riv/wos
| |
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)